Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys

Calcified Tissue International

Volumn 85, Issue 4, 2009, Pages 344-355

  Stroup, G B ^a   Kumar, S ^a   Jerome, C P ^b  

^a GLAXOSMITHKLINE   (United States)

^b Think Bone Consulting Inc   (United States)

Author keywords

Antiresorptive; Cathepsin K; Cysteine protease; Macaca fascicularis; Primate

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CATHEPSIN K INHIBITOR; RELACATIB;

ANIMAL EXPERIMENT; ARTICLE; BONE MASS; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; DRUG MECHANISM; HUMAN; MONKEY; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; TRABECULAR BONE;

ALENDRONATE; ANIMALS; AZEPINES; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CATHEPSIN K; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MACACA FASCICULARIS; MODELS, ANIMAL; OSTEOGENESIS; OVARIECTOMY; PEPTIDES; SULFONES;

EID: 70349973826     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-009-9279-x     Document Type: Article

References (54)

1. National Osteoporosis Foundation (2002) America's bone health: the state of osteoporosis and low bone mass in our nation. National Osteoporosis Foundation, Washington, DC
2. JY Reginster N Burlet 2006 Osteoporosis: a still increasing prevalence Bone 38 2 Suppl 1 4 9 10.1016/j.bone.2005.11.024 (Pubitemid 43190767)
3. Y Yasuda J Kaleta D Bromme 2005 The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics Adv Drug Deliv Rev 57 7 973 993 15876399 10.1016/j.addr.2004.12.013 (Pubitemid 40703885)
4. A Grey IR Reid 2005 Emerging and potential therapies for osteoporosis Expert Opin Investig Drugs 14 3 265 278 15833058 10.1517/13543784.14.3.265 (Pubitemid 40520966)
5. PN Sambrook JP Rodriguez RD Wasnich MM Luckey A Kaur L Meng A Lombardi 2004 Alendronate in the prevention of osteoporosis: 7-year follow-up Osteoporos Int 15 6 483 488 15205720 10.1007/s00198-003-1571-4
6. ND Nguyen JA Eisman TV Nguyen 2006 Anti-hip fracture efficacy of bisphosphonates: a Bayesian analysis of clinical trials J Bone Miner Res 21 1 340 349 16526127 10.1359/JBMR.050903 (Pubitemid 43265301)
7. JP Schneider 2006 Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate Geriatrics 61 1 31 33 16405362
8. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 3 1294 1301 15598694 10.1210/jc.2004-0952 (Pubitemid 40463979)
9. AG Porras SD Holland BJ Gertz 1999 Pharmacokinetics of alendronate Clin Pharmacokinet 36 5 315 328 10384857 10.2165/00003088-199936050-00002 (Pubitemid 29261508)
10. JK Marshall 2002 The gastrointestinal tolerability and safety of oral bisphosphonates Exp Opin Drug Safety 1 1 71 78 10.1517/14740338.1.1.71
11. JY Reginster D Felsenberg C Cooper JA Stakkestad PD Miller DL Kendler S Adami MR McClung MA Bolognese R Civitelli E Dumont B Bonvoisin RR Recker PD Delmas 2006 A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate Osteoporos Int 17 2 159 166 15959614 10.1007/s00198-005-1957-6 (Pubitemid 43053578)
12. JY Reginster 2006 Adherence and persistence: impact on outcomes and health care resources Bone 38 2 Suppl 2 18 21 10.1016/j.bone.2005.11.013 (Pubitemid 43177168)
13. JP Bilezikian 2005 Anabolic therapy for osteoporosis Int J Fertil Womens Med 50 2 53 60 16334411
14. MR Rubin JP Bilezikian 2005 Parathyroid hormone as an anabolic skeletal therapy Drugs 65 17 2481 2498 16296873 10.2165/00003495-200565170-00005 (Pubitemid 41697316)
15. KE Poole J Reeve 2005 Parathyroid hormone-a bone anabolic and catabolic agent Curr Opin Pharmacol 5 6 612 617 16181808 10.1016/j.coph.2005.07.004 (Pubitemid 41614461)
16. AB Hodsman DC Bauer DW Dempster L Dian DA Hanley ST Harris DL Kendler MR McClung PD Miller WP Olszynski E Orwoll CK Yuen 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use Endocr Rev 26 5 688 703 15769903 10.1210/er.2004-0006 (Pubitemid 41127277)
17. JP Bilezikian MR Rubin JS Finkelstein 2005 Parathyroid hormone as an anabolic therapy for women and men J Endocrinol Invest 28 8 Suppl 41 49 16329201
18. MP Lecart O Bruyere JY Reginster 2004 Combination/sequential therapy in osteoporosis Curr Osteoporos Rep 2 4 123 130 16036093 10.1007/s11914-996-0011-8
19. DM Black JP Bilezikian KE Ensrud SL Greenspan L Palermo T Hue TF Lang JA McGowan CJ Rosen 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 6 555 565 16093464 10.1056/NEJMoa050336 (Pubitemid 41138937)
20. Takahashi N, Udagawa M, Takami M, Suda T (2002) Cells of bone: osteoclast generation. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn. Academic Press, San Diego, pp 109-126
21. D Wang SC Miller P Kopeckova J Kopecek 2005 Bone-targeting macromolecular therapeutics Adv Drug Deliv Rev 57 7 1049 1076 15876403 10.1016/j.addr.2004.12. 011 (Pubitemid 40692291)
22. Väänänen K, Zhao H (2002) Osteoclast function: biology and mechanism. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn. Academic Press, San Diego, pp 127-139
23. FH Drake RA Dodds IE James JR Connor C Debouck S Richardson E Lee-Rykaczewski L Coleman D Rieman R Barthlow G Hastings M Gowen 1996 Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts J Biol Chem 271 21 12511 12516 8647859 10.1074/jbc.271.21.12511 (Pubitemid 26160923)
24. M Gowen F Lazner R Dodds R Kapadia J Feild M Tavaria I Bertoncello F Drake S Zavarselk I Tellis P Hertzog C Debouck I Kola 1999 Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization J Bone Miner Res 14 10 1654 1663 10491212 10.1359/jbmr.1999.14. 10.1654 (Pubitemid 29455813)
25. P Saftig E Hunziker O Wehmeyer S Jones A Boyde W Rommerskirch JD Moritz P Schu K von Figura 1998 Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice Proc Natl Acad Sci USA 95 23 13453 13458 9811821 10.1073/pnas.95.23.13453 (Pubitemid 28522993)
26. RW Marquis Y Ru DS Yamashita HJ Oh J Yen SK Thompson TJ Carr MA Levy TA Tomaszek CF Ijames WW Smith B Zhao CA Janson SS Abdel-Meguid KJ D'Alessio MS McQueney DF Veber 1999 Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K Bioorg Med Chem 7 4 581 588 10353637 10.1016/S0968-0896(99) 00011-5 (Pubitemid 29150301)
27. BJ Votta MA Levy A Badger J Bradbeer RA Dodds IE James S Thompson MJ Bossard T Carr JR Connor TA Tomaszek L Szewczuk FH Drake DF Veber M Gowen 1997 Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo J Bone Miner Res 12 9 1396 1406 9286755 10.1359/jbmr.1997.12.9.1396 (Pubitemid 27375382)
28. DS Yamashita RW Marquis R Xie SD Nidamarthy HJ Oh JU Jeong KF Erhard KW Ward TJ Roethke BR Smith HY Cheng X Geng F Lin PH Offen B Wang N Nevins MS Head RC Haltiwanger AA Narducci Sarjeant LM Liable-Sands B Zhao WW Smith CA Janson E Gao T Tomaszek M McQueney IE James CJ Gress DL Zembryki MW Lark DF Veber 2006 Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors J Med Chem 49 5 1597 1612 16509577 10.1021/jm050915u (Pubitemid 43376505)
29. S Kumar L Dare JA Vasko-Moser IE James SM Blake DJ Rickard SM Hwang T Tomaszek DS Yamashita RW Marquis H Oh JU Jeong DF Veber M Gowen MW Lark G Stroup 2006 A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys Bone 40 1 122 131 16962401 10.1016/j.bone.2006.07.015
30. S Kumar S Rehm R Boyce J Birmingham G Stroup C Jerome P Wier 2005 Treatment of young male monkeys for 12 months with a highly potent inhibitor of Cathepsin K inhibits bone resorption and increases bone mineral density and strength J Bone Miner Res 20 Suppl. 1 S81
31. CP Jerome 1998 Primate models of osteoporosis Lab Anim Sci 48 6 618 622 10090086
32. CJ Rosen MC Hochberg SL Bonnick M McClung P Miller S Broy R Kagan E Chen RA Petruschke DE Thompson AE de Papp 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 1 141 151 15619680 10.1359/JBMR.040920
33. Bayne K (1996) Revised guide for the care and use of laboratory animals available. American Physiological Society. Physiologist 39(4):199, 208-211
34. DD Thompson JG Seedor H Quartuccio H Solomon C Fioravanti J Davidson H Klein R Jackson J Clair D Frankenfield, et al. 1992 The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons J Bone Miner Res 7 8 951 960 1442209
35. AM Parfitt MK Drezner FH Glorieux JA Kanis H Malluche PJ Meunier SM Ott RR Recker 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee J Bone Miner Res 2 6 595 610 3455637
36. CP Jerome RA Power IO Obasanjo TC Register M Guidry CS Carlson DS Weaver 1997 The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys Bone 20 4 355 364 9108356 10.1016/S8756-3282(97)00008-2 (Pubitemid 27196659)
37. CP Jerome DB Burr T Van Bibber JM Hock R Brommage 2001 Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis) Bone 28 2 150 159 11182372 10.1016/S8756-3282(00)00430-0 (Pubitemid 32140971)
38. A Parfitt J Foldes 1991 The ambiguity of interstitial bone thickness: a new approach to the mechanism of trabecular thinning Bone 12 119 122 2064839 10.1016/8756-3282(91)90010-G
39. DN Deaton S Kumar 2004 Cathepsin K inhibitors: their potential as anti-osteoporosis agents Prog Med Chem 42 245 375 15003723 10.1016/S0079- 6468(04)42006-2
40. CP Jerome PE Peterson 2001 Nonhuman primate models in skeletal research Bone 29 1 1 6 11472884 10.1016/S8756-3282(01)00477-X (Pubitemid 32707917)
41. P Garnero E Sornay-Rendu MC Chapuy PD Delmas 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis J Bone Miner Res 11 3 337 349 8852944
42. GB Stroup SJ Hoffman JA Vasko-Moser BA Lechowska EL Jenkins LC Dare M Gowen 2001 Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy Bone 28 5 532 537 11344053 10.1016/S8756-3282(01)00421-5 (Pubitemid 32410004)
43. SL Bonnick L Shulman 2006 Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119 4 Suppl 1 S25 S31 16563938 10.1016/j.amjmed.2005.12.020
44. CH Chesnut 3rd CJ Rosen 2001 Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture J Bone Miner Res 16 12 2163 2172 11760829 10.1359/jbmr.2001.16.12.2163
45. MR McClung J San Martin PD Miller R Civitelli F Bandeira M Omizo DW Donley GP Dalsky EF Eriksen 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass Arch Intern Med 165 15 1762 1768 16087825 10.1001/archinte.165.15.1762 (Pubitemid 41138965)
46. CP Jerome CS Carlson TC Register FT Bain MJ Jayo DS Weaver MR Adams 1994 Bone functional changes in intact, ovariectomized, and ovariectomized, hormone-supplemented adult cynomolgus monkeys (Macaca fascicularis) evaluated by serum markers and dynamic histomorphometry J Bone Miner Res 9 4 527 540 8030441
47. R Recker P Masarachia A Santora T Howard P Chavassieux M Arlot G Rodan L Wehren D Kimmel 2005 Trabecular bone microarchitecture after alendronate treatment of osteoporotic women Curr Med Res Opin 21 2 185 194 15801989 10.1185/030079904X20259 (Pubitemid 40469895)
48. CP Jerome CS Johnson HT Vafai KC Kaplan J Bailey B Capwell F Fraser L Hansen H Ramsay M Shadoan CJ Lees JS Thomsen L Mosekilde 1999 Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis) Bone 25 3 301 309 10495134 10.1016/S8756-3282(99)00166-0 (Pubitemid 29406056)
49. R Rizzoli 2006 Long-term outcome of weekly bisphosphonates Clin Orthop Relat Res 443 61 65 16462427 10.1097/01.blo.0000200249.12006.6e
50. P Ravn 2002 Bisphosphonates for prevention of postmenopausal osteoporosis Dan Med Bull 49 1 1 18 11894721
51. DN Deaton FX Tavares 2005 Design of cathepsin k inhibitors for osteoporosis Curr Top Med Chem 5 16 1639 1675 16375747 10.2174/ 156802605775009676
52. C Jerome M Missbach R Gamse 2005 AAE581, a novel cathepsin K inhibitor, protects against ovariectomy-induced bone loss in non-human primates, in part by stimulation of periosteal bone formation J Bone Miner Res 20 Suppl. 1 S46
53. G Stroup L Dare J Vasko-Moser S Hoffman S Kumar 2006 Repeat daily dosing with a highly potent inhibitor of cathepsin K results in significant, transient elevation of plasma PTH in cynomolgus monkeys J Bone Miner Res 21 Suppl. 1 S160
54. A Itabashi N Kurata Y Sugita Y Kawai 2006 Balicatib, a novel cathepsin K-inhibitor, increases serum intact PTH beyond diurnal patterns following 14-daily administration in Japanese postmenopausal women J Bone Miner Res 21 Suppl. 1 S24